DEA Yanks Registration from Opioid-Rule-Breaking Pharmacy
Published Date: 4/2/2025
Notice
Summary
Prescript Pharmaceuticals got their DEA registration suspended and revoked because they ordered powerful opioids without proper approval between 2020 and 2023. This affects the company directly and means they can’t legally handle these drugs anymore, protecting public health. The decision is final and signals serious consequences for companies that don’t follow drug safety rules.
Analyzed Economic Effects
5 provisions identified: 0 benefits, 5 costs, 0 mixed.
DEA Registration Revoked for Prescript
The DEA revoked Prescript Pharmaceuticals' Certificate of Registration No. RP0177798, effective May 2, 2025. The agency found that Prescript ordered Schedule II opioids (hydrocodone and oxycodone) from 2020 through 2023 without requesting or receiving procurement quota as required by 21 CFR 1303.12(b), so the company can no longer lawfully handle those controlled substances.
Pending Renewal and New Applications Denied
The Order denies any pending applications of Prescript Pharmaceuticals to renew or modify Certificate No. RP0177798 and denies any other pending application for additional registration in California. That denial takes effect with the Order effective May 2, 2025.
DEA May Adjudicate Expired Registrations
The Agency states it has jurisdiction to adjudicate a registrant's conduct to finality even if the registrant's DEA registration has expired. The Order explains the Agency's jurisdiction is over the registrant (not the registration) and that final orders may be issued after a registration expires.
Final Order Clarifies Seized Inventory Disposition
The Order notes that controlled substances seized from Prescript when the OSC/ISO was served remain outstanding and that issuing a final order will clarify the disposition of those seized assets. The record shows Prescript's registration expired on March 31, 2024, but the disposition of seized controlled substances is unresolved.
Order Sends Strong Deterrent Message
The Agency explains that revocation is intended to serve both specific and general deterrence, warning other registrants that repeatedly ignoring quota rules can lead to revocation. The decision emphasizes that allowing Prescript to retain registration would signal that registrants may choose which rules apply to them.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-05589 — Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of Filing of a Proposed Rule Change, as Modified by Amendment No. 1, To List and Trade Shares of the Osprey Bitcoin Trust Under BZX Rule 14.11(e)(4), Commodity-Based Trust Shares
The Cboe BZX Exchange wants to start listing and trading shares of the Osprey Bitcoin Trust, a fund tied to Bitcoin’s price. This change lets investors buy and sell these shares on the exchange, making Bitcoin investing easier and more accessible. The SEC is reviewing this proposal and asking for public comments before it goes live.
Next: 2025-05594 — Notice of Inventory Completion: Peabody Museum of Archaeology and Ethnology, Harvard University, Cambridge, MA
The Peabody Museum at Harvard has finished checking its collection and found that some items belong to Native American tribes and Native Hawaiian groups. This means these groups can now ask for their cultural objects back. If you’re part of these communities, keep an eye out for how and when to claim these important items.